ENSG00000047410 |
TPR |
Thyroid Gland Oncocytic Follicular Carcinoma |
gene_fusion |
47.62% (20/42) |
2 entries |
ENSG00000047410 |
TPR |
Follicular Variant Thyroid Gland Papillary Carcinoma |
gene_fusion |
50.0% (14/28) |
2 entries |
ENSG00000047410 |
TPR |
Benign Thyroid Gland Neoplasm |
gene_fusion |
50.0% (65/130) |
3 entries |
ENSG00000047410 |
TPR |
papillary thyroid carcinoma |
gene_fusion |
49.87% (378/758) |
9 entries |
ENSG00000047410 |
TPR |
follicular thyroid carcinoma |
gene_fusion |
37.5% (6/16) |
3 entries |
ENSG00000047410 |
TPR |
medullary thyroid gland carcinoma |
gene_fusion |
12.0% (3/25) |
1 entry |
ENSG00000047410 |
TPR |
basal cell carcinoma |
missense_variant |
6.897% (4/58) |
1 entry |
ENSG00000047410 |
TPR |
anaplastic oligodendroglioma |
missense_variant |
4.762% (2/42) |
1 entry |
ENSG00000047410 |
TPR |
female breast carcinoma |
missense_variant |
2.247% (6/267) |
2 entries |
ENSG00000047410 |
TPR |
rectal adenocarcinoma |
missense_variant |
6.335% (14/221) |
2 entries |
ENSG00000047410 |
TPR |
lung adenocarcinoma |
gene_fusion |
3.519% (41/1165) |
1 entry |
ENSG00000047410 |
TPR |
nasopharyngeal squamous cell carcinoma |
stop_gained |
2.381% (4/168) |
1 entry |
ENSG00000047410 |
TPR |
lung adenocarcinoma |
missense_variant |
3.519% (41/1165) |
3 entries |
ENSG00000047410 |
TPR |
prostate adenocarcinoma |
missense_variant |
3.508% (51/1454) |
3 entries |
ENSG00000047410 |
TPR |
Poorly Differentiated Thyroid Gland Carcinoma |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000047410 |
TPR |
colorectal adenocarcinoma |
missense_variant |
7.199% (82/1139) |
3 entries |
ENSG00000047410 |
TPR |
skin melanoma |
missense_variant |
2.896% (28/967) |
3 entries |
ENSG00000047410 |
TPR |
small cell lung carcinoma |
missense_variant |
3.448% (11/319) |
3 entries |
ENSG00000047410 |
TPR |
diffuse large B-cell lymphoma |
sequence_alteration |
0.6601% (2/303) |
1 entry |
ENSG00000047410 |
TPR |
colon adenocarcinoma |
stop_gained |
8.234% (62/753) |
2 entries |
ENSG00000047410 |
TPR |
gastric adenocarcinoma |
sequence_alteration |
3.387% (23/679) |
1 entry |
ENSG00000047410 |
TPR |
oral squamous cell carcinoma |
missense_variant |
0.9709% (2/206) |
1 entry |
ENSG00000047410 |
TPR |
breast ductal adenocarcinoma |
sequence_alteration |
5.993% (35/584) |
1 entry |
ENSG00000047410 |
TPR |
squamous cell lung carcinoma |
missense_variant |
4.462% (34/762) |
4 entries |
ENSG00000047410 |
TPR |
prostate adenocarcinoma |
sequence_alteration |
3.508% (51/1454) |
2 entries |
ENSG00000047410 |
TPR |
skin melanoma |
sequence_alteration |
2.896% (28/967) |
3 entries |
ENSG00000047410 |
TPR |
clear cell renal carcinoma |
missense_variant |
0.7977% (11/1379) |
1 entry |
ENSG00000047410 |
TPR |
colon adenocarcinoma |
frameshift_variant |
8.234% (62/753) |
3 entries |
ENSG00000047410 |
TPR |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.549% (7/452) |
3 entries |
ENSG00000047410 |
TPR |
lung adenocarcinoma |
sequence_alteration |
3.519% (41/1165) |
4 entries |
ENSG00000047410 |
TPR |
prostate carcinoma |
missense_variant |
1.166% (5/429) |
2 entries |
ENSG00000047410 |
TPR |
colorectal adenocarcinoma |
sequence_alteration |
7.199% (82/1139) |
2 entries |
ENSG00000047410 |
TPR |
esophageal squamous cell carcinoma |
sequence_alteration |
2.802% (19/678) |
3 entries |
ENSG00000047410 |
TPR |
squamous cell lung carcinoma |
stop_gained |
4.462% (34/762) |
2 entries |
ENSG00000047410 |
TPR |
colon adenocarcinoma |
missense_variant |
8.234% (62/753) |
7 entries |
ENSG00000047410 |
TPR |
esophageal adenocarcinoma |
sequence_alteration |
3.653% (16/438) |
1 entry |
ENSG00000047410 |
TPR |
skin melanoma |
stop_gained |
2.896% (28/967) |
1 entry |
ENSG00000047410 |
TPR |
esophageal adenocarcinoma |
missense_variant |
3.653% (16/438) |
1 entry |
ENSG00000047410 |
TPR |
small cell lung carcinoma |
stop_gained |
3.448% (11/319) |
2 entries |
ENSG00000047410 |
TPR |
gastric intestinal type adenocarcinoma |
missense_variant |
7.059% (6/85) |
2 entries |
ENSG00000047410 |
TPR |
colorectal adenocarcinoma |
stop_gained |
7.199% (82/1139) |
2 entries |
ENSG00000047410 |
TPR |
clear cell renal carcinoma |
sequence_alteration |
0.7977% (11/1379) |
1 entry |
ENSG00000047410 |
TPR |
hepatocellular carcinoma |
sequence_alteration |
1.996% (18/902) |
2 entries |
ENSG00000047410 |
TPR |
colorectal adenocarcinoma |
frameshift_variant |
7.199% (82/1139) |
1 entry |
ENSG00000047410 |
TPR |
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
1.549% (7/452) |
1 entry |
ENSG00000047410 |
TPR |
rectal adenocarcinoma |
sequence_alteration |
6.335% (14/221) |
1 entry |
ENSG00000047410 |
TPR |
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000047410 |
TPR |
chronic lymphocytic leukemia |
sequence_alteration |
1.014% (9/888) |
1 entry |
ENSG00000047410 |
TPR |
breast ductal adenocarcinoma |
missense_variant |
5.993% (35/584) |
1 entry |
ENSG00000047410 |
TPR |
esophageal squamous cell carcinoma |
stop_gained |
2.802% (19/678) |
2 entries |
ENSG00000047410 |
TPR |
brain glioblastoma |
sequence_alteration |
0.3236% (3/927) |
2 entries |
ENSG00000047410 |
TPR |
melanoma |
missense_variant |
3.922% (4/102) |
1 entry |
ENSG00000047410 |
TPR |
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.381% (4/168) |
1 entry |
ENSG00000047410 |
TPR |
cecum adenocarcinoma |
sequence_alteration |
16.03% (21/131) |
2 entries |
ENSG00000047410 |
TPR |
prostate carcinoma |
sequence_alteration |
1.166% (5/429) |
1 entry |
ENSG00000047410 |
TPR |
esophageal squamous cell carcinoma |
missense_variant |
2.802% (19/678) |
3 entries |
ENSG00000047410 |
TPR |
pancreatic ductal adenocarcinoma |
missense_variant |
2.621% (33/1259) |
2 entries |
ENSG00000047410 |
TPR |
hepatocellular carcinoma |
missense_variant |
1.996% (18/902) |
1 entry |
ENSG00000047410 |
TPR |
gastric intestinal type adenocarcinoma |
stop_gained |
7.059% (6/85) |
1 entry |
ENSG00000047410 |
TPR |
breast carcinoma |
missense_variant |
1.772% (25/1411) |
2 entries |
ENSG00000047410 |
TPR |
colon adenocarcinoma |
sequence_alteration |
8.234% (62/753) |
3 entries |
ENSG00000047410 |
TPR |
lung adenocarcinoma |
stop_gained |
3.519% (41/1165) |
1 entry |
ENSG00000047410 |
TPR |
cecum adenocarcinoma |
missense_variant |
16.03% (21/131) |
2 entries |
ENSG00000047410 |
TPR |
gastric adenocarcinoma |
missense_variant |
3.387% (23/679) |
2 entries |
ENSG00000047410 |
TPR |
rectal adenocarcinoma |
stop_gained |
6.335% (14/221) |
1 entry |
ENSG00000047410 |
TPR |
Pleural Mesothelioma |
missense_variant |
1.031% (1/97) |
1 entry |
ENSG00000047410 |
TPR |
prostate adenocarcinoma |
frameshift_variant |
3.508% (51/1454) |
1 entry |
ENSG00000047410 |
TPR |
meningioma (disease) |
missense_variant |
2.041% (1/49) |
1 entry |
ENSG00000047410 |
TPR |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000047410 |
TPR |
papillary renal cell carcinoma |
missense_variant |
0.5634% (2/355) |
1 entry |
ENSG00000047410 |
TPR |
small cell lung carcinoma |
sequence_alteration |
3.448% (11/319) |
1 entry |
ENSG00000047410 |
TPR |
hepatocellular carcinoma |
frameshift_variant |
1.996% (18/902) |
1 entry |
ENSG00000047410 |
TPR |
rectal adenocarcinoma |
frameshift_variant |
6.335% (14/221) |
1 entry |
ENSG00000047410 |
TPR |
Parathyroid Gland Carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000047410 |
TPR |
basal cell carcinoma |
sequence_alteration |
6.897% (4/58) |
1 entry |
ENSG00000047410 |
TPR |
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000047410 |
TPR |
adenosquamous lung carcinoma |
sequence_alteration |
9.091% (1/11) |
1 entry |
ENSG00000047410 |
TPR |
ovarian serous adenocarcinoma |
stop_gained |
0.1486% (1/673) |
1 entry |
ENSG00000047410 |
TPR |
melanoma |
stop_gained |
3.922% (4/102) |
1 entry |
ENSG00000047410 |
TPR |
pancreatic neuroendocrine tumor |
missense_variant |
2.5% (4/160) |
1 entry |
ENSG00000047410 |
TPR |
mucosal melanoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000047410 |
TPR |
gastric intestinal type adenocarcinoma |
frameshift_variant |
7.059% (6/85) |
1 entry |
ENSG00000047410 |
TPR |
osteosarcoma |
stop_gained |
0.8475% (1/118) |
1 entry |
ENSG00000047410 |
TPR |
hepatocellular carcinoma |
stop_gained |
1.996% (18/902) |
1 entry |
ENSG00000047410 |
TPR |
colon adenoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000047410 |
TPR |
Merkel cell skin cancer |
sequence_alteration |
6.667% (2/30) |
1 entry |
ENSG00000047410 |
TPR |
non-small cell lung carcinoma |
sequence_alteration |
5.66% (3/53) |
1 entry |
ENSG00000047410 |
TPR |
rectal adenocarcinoma |
conservative_inframe_deletion |
6.335% (14/221) |
1 entry |
ENSG00000047410 |
TPR |
Mantle cell lymphoma |
sequence_alteration |
2.439% (1/41) |
1 entry |
ENSG00000047410 |
TPR |
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000047410 |
TPR |
Gallbladder Adenocarcinoma |
missense_variant |
1.149% (1/87) |
1 entry |
ENSG00000047410 |
TPR |
bladder transitional cell carcinoma |
missense_variant |
0.7299% (1/137) |
1 entry |
ENSG00000047410 |
TPR |
basal cell carcinoma |
stop_gained |
6.897% (4/58) |
1 entry |
ENSG00000047410 |
TPR |
diffuse gastric adenocarcinoma |
sequence_alteration |
1.266% (1/79) |
1 entry |
ENSG00000047410 |
TPR |
T-cell acute lymphoblastic leukemia |
sequence_alteration |
0.2632% (1/380) |
1 entry |
ENSG00000047410 |
TPR |
colonic neoplasm |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000047410 |
TPR |
Brain Stem Glioblastoma |
sequence_alteration |
1.786% (1/56) |
1 entry |
ENSG00000047410 |
TPR |
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000047410 |
TPR |
Merkel cell skin cancer |
missense_variant |
6.667% (2/30) |
1 entry |